A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages 783-789

  Bain, Earle E ^a   Apostol, George ^a,b   Sangal, R Bart ^c   Robieson, Weining Z ^a   McNeill, Dawnelle L ^a   Abi Saab, Walid M ^a,b,d   Saltarelli, Mario D ^a,e  

^a ABBOTT LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^d Shire AG   (Switzerland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBU TAB; IBUPROFEN; LEVOTHYROXINE SODIUM; LORATADINE; MULTIVITAMIN; NAPROXEN; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; PARACETAMOL; PLACEBO; POZANICLINE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; HUMAN; INVESTIGATOR RATED CONNERS ADULT ADHD RATING SCALE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QT PROLONGATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

EID: 84863551521     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06719     Document Type: Article

References (29)

1. Faraone SV, Biederman J. What is the prevalence of adult ADHD? results of a population screen of 966 adults. J Atten Disord. 2005;9(2):384-391. doi:10.17/1087054705281478 PubMed (Pubitemid 41608110)
2. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565-572. doi:10.1097/01.jom.016863.3541.39 PubMed (Pubitemid 40847440)
3. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. doi:10.176/api.ajp.163.4.716 PubMed (Pubitemid 44464584)
4. Culpepper L. Primary care treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(suppl 8):51-58. PubMed (Pubitemid 44385607)
5. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry. 2005;57(11):1442-1451. doi:10.1016/j.biopsych.205.04.01 PubMed (Pubitemid 40798566)
6. Gudjonsson GH, Sigurdsson JF, Eyjolfsdottir GA, et al. The relationship between satisfaction with life, ADHD symptoms, and associated problems among university students. J Atten Disord. 2009;12(6):507-515. doi:10.17/ 1087054708323018 PubMed
7. Biederman J. Impact of comorbidity in adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2004;65(suppl 3):3-7. PubMed
8. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 2006;184(3-4): 523-539. doi:10.107/s0213-05-0164-7 PubMed (Pubitemid 43255869)
9. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behav Brain Res. 2006;175(2):201-211. doi:10.1016/j.br.206.09.015 PubMed (Pubitemid 44750245)
10. Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT- 089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012;219(3):715-725. PubMed
11. Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/ hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59(11):1065-1070. doi:10.1016/j.biopsych.205.10.029 PubMed (Pubitemid 43849655)
12. Conners CK, Ehrhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems; 1999.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC: American Psychiatric Association; 2000.
14. Adler L, Spencer T. The Adult ADHD Clinical Diagnostic Scale (ACDS) V 1.2. New York, NY: New York University School of Medicine; 2004.
15. Guy W. ECDEU Assessment Manual For Psychopharmacology, Revised. Bethesda, MD: Department of Health, Education, and Welfare; 1976.
16. Spencer TJ, Adler LA, Qiao M, et al. Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS). J Atten Disord. 2010; 14(1):57-68. PubMed
17. Adler LA, Shaw DM, Spencer TJ, et al. Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults. Compr Psychiatry. 2011;52(6):769-773.doi:10.1016/j.compsych.2010.12.02 PubMed
18. Gioia G, Isquith P, Guy S, et al. Behavior Rating Inventory of Executive Function. Odessa, FL: Psychological Assessment Resources; 2000.
19. Brod M, Johnston J, Able S, et al. Validation of the adult attention-deficit/ hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006;15(1):117-129. doi:10.107/s136-05-8325-z PubMed (Pubitemid 43097592)
20. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365. doi:10.2165/019053-19304050-06 PubMed
21. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127. doi:10.1/j.1360-043.191. tb01879.x PubMed
22. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3(1):7-16. doi:10.1080/146202032051 PubMed (Pubitemid 32611534)
23. MedDRA MSSO. Medical Dictionary for Regulatory Activities (MedDRA).; Version 11.0. http://www.meddramsso.com/
24. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. doi:10.1016/S06-323(02)01671-2 PubMed (Pubitemid 36126473)
25. Newcorn JH, Sutton VK, Zhang S, et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12): 1165-1172. PubMed
26. Waxmonsky JG, Waschbusch DA, Glatt SJ, et al. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. J Clin Psychiatry. 2011;72(10):1366-1375. PubMed
27. Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry. 2011;50(1):73-84 e71. PubMed
28. Wilens TE, Vitulano M, Upadhyaya H, et al. Cigarette smoking associated with attention deficit hyperactivity disorder. J Pediatr. 2008;153(3):414-419. doi:10.1016/j.jpeds.208.04.030 PubMed
29. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10): 1142-1147. doi:10.101/archpsyc.62.10.142 PubMed (Pubitemid 41396939)